<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> with mutated PIK3CA, identified from two large observational cohorts, had increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific and overall survival if they used aspirin regularly after diagnosis compared to non-users </plain></SENT>
<SENT sid="1" pm="."><plain>No effect of aspirin was seen in patients with <z:mp ids='MP_0002169'>wild-type</z:mp> PIK3CA </plain></SENT>
<SENT sid="2" pm="."><plain>Mutated PIK3CA might be a useful biomarker to select patients who would benefit from adjuvant aspirin therapy </plain></SENT>
</text></document>